Bladder Urothelial Carcinoma

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 >= 1%	Bladder Urothelial Carcinoma	Nivolumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR2::BICC1	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR2::CASP7	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3::BAIAP2L1	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3 p.R248C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3 p.S249C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3 p.G370C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3 p.Y373C	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	FGFR3::TACC3	Bladder Urothelial Carcinoma	Erdafitinib
Sensitivity (+)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab
Sensitivity (+)	PD-L1 (CPS) >= 10	Bladder Urothelial Carcinoma	Pembrolizumab
Sensitivity (+)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab